[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-503537-105":59,"doc-detail-503537-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gems-of-the-week-volume-3-issue-50","GEMs of the Week - Volume 3 - Issue 50","","GEMs of the Week Volume 3, Issue 50 summarizes peer-reviewed clinical evidence across multiple topics, led by a meta-analysis linking daily walking steps with progressive reductions in all-cause mortality and clarifying where risk plateaus by age. The issue also reviews comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for preventing recurrent gout flares versus alternative therapies in patients with gout and type 2 diabetes, including study design details, outcomes, and limitations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gems-of-the-week-volume-3-issue-50/503537/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gems-of-the-week-volume-3-issue-50/503537.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-10-03",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the key takeaway about daily steps and mortality risk?","Question",{"text":112,"@type":113},"Taking more steps per day is associated with progressively lower risk of all-cause mortality, with a plateau observed for adults aged 60 and older at about 6,000–8,000 steps per day.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do SGLT2 inhibitors compare with DPP-4 inhibitors for recurrent gout flares?",{"text":117,"@type":113},"SGLT2 inhibitor initiation leads to a 34% lower rate of recurrent gout flares in patients with gout and type 2 diabetes compared with DPP-4 inhibitors, with similar findings across demographic subgroups.",{"name":119,"@type":110,"acceptedAnswer":120},"What limitations are noted for the steps-and-mortality evidence?",{"text":121,"@type":113},"The conclusions are based on observational studies with higher risk of bias and confounding; steps were measured at a single time point, and participants were largely from high-income countries, limiting generalizability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},503537,1791936914,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","GEMs ofthe Week Volume 3- Issue 50  \nWhat's in this week's issue? Week of December 11-15, 2023  \nSPOTLIGHT: How Many Steps Does It Take to  \nGet to a Longer Life?  \n Sodium-Glucose Cotransporter-2 Inhibitors: The Elixir for Recurrent Gout Flares?  \n Orforglipron Use for Obesity  \n Transmasculine Gender Affirmation: Is Surgical Efficiency Worth the Risk?  \nHow Many Steps Does It Take to Get to a Longer Life?  \nDaily Steps and All-Cause Mortality: A Meta-Analysis of 15 International Cohorts  \nPaluch AE, Bajpai S, Bassett DR, et al. Daily steps and allcause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7(3):e219-e228 . doi:10.1016/S2468-2667(21)00302-9  \nCopyright © 2023 by Family Physicians Inquiries Network, Inc.  \nKEY TAKEAWAY: Taking more steps per day is associated with a progressively lower risk of all-cause mortality. STUDY DESIGN: Meta-analysis of 15 observational studies and one systematic review (N=47,471)  \nLEVEL OF EVIDENCE: STEP 1  \n\n| BRIEF BACKGROUND INFORMATION: Although 10,000 steps per day are widely promoted as having health benefits, there is little evidence to support this recommendation. This article demonstrates the association between the number of steps per day with all-cause mortality. |\n| --- |\n| PATIENTS: Ambulatory adults\u003Cbr>INTERVENTION: Higher quartiles of steps per day CONTROL: Lower quartiles of steps per day\u003Cbr>PRIMARY OUTCOME: All-cause mortality |\n\nMETHODS (BRIEF DESCRIPTION):  \n• Eligibility criteria included longitudinal design, participants ≥18 years old, non-patient populations, and the study reported an association between daily step counts and mortality.  \n• In each study, participants wore a step-counting  \ndevice for at least one week, steps per day were averaged, and then participants were followed up for death from any cause. The step rate was also analyzed when data was available.  \n• The Steps for Health Collaborative standardized protocol was used to process participant-level data.  \n• Step volume was categorized into quartiles and associations with all-cause mortality were examined and referenced against the lowest quartile using Cox proportional hazards regression. Investigators of participating studies completed models for each study’s overall sample by age group and sex.  \n• Median steps per day were calculated by quartile from each study's medians.  \nINTERVENTION (\\# IN THE GROUP): Not available COMPARISON (\\# IN THE GROUP): Not available   \nFOLLOW-UP PERIOD: Median 7.1 years (2 .7–13 years)  \nRESULTS:  \nPrimary Outcome –  \n• Taking more steps per day was associated with progressively lower mortality risk, with the risk plateauing for adults ≥60 years old at 6,000–8,000 steps per day (HR 0.43; 95% CI, 0.34–0.53) .  \n• For younger adults \u003C60 years old, mortality risk reduction was associated with 8,000–10,000 steps per day (HR 0.60; 95% CI, 0.44–0.83) .  \n• Compared with the lowest quartile, the adjusted hazard ratio for all-cause mortality was:  \no Quartile 2 (aHR 0.60; 95% CI, 0.51–0.71)  \no Quartile 3 (aHR 0.55; 95% CI, 0.49–0.62)  \no Quartile 4 (aHR 0.47; 95% CI, 0.39–0.57)  \n• Association between step counts and mortality was stronger in the six studies with fewer than six years of follow-up (HR 0.32; 95% CI, 0.25–0.41) than among the nine studies with six years of follow-up or more (HR 0.57; 95% CI, 0.49–0.66) when comparing the lowest and highest quartile.  \n• Step rate did not have a significant impact on mortality when controlled for the total step count.  \n• There was no significant difference in mortality reduction between females and males.  \nLIMITATIONS:  \n• The data was derived from observational studies which are at higher risk for bias and confounding variables.  \n• Steps were measured at a single time point and did not account for changes in steps per day over time.  \n• All included studies were in high-income countries and participants were volunteers primarily among White populations, restricting the generalizability of th","cbCaimlO2bZSz5hl","https://ap.wps.com/l/cbCaimlO2bZSz5hl","pdf",501280,"English","# Spotlight\n## How Many Steps Does It Take to Get to a Longer Life?\n## Sodium-Glucose Cotransporter-2 Inhibitors and Recurrent Gout Flares\n## Orforglipron Use for Obesity\n## Transmasculine Gender Affirmation\n## Daily Steps and All-Cause Mortality: A Meta-Analysis of 15 International Cohorts\n## Comparative Effectiveness Study: SGLT2i vs DPP-4i","[{\"question\":\"What is the key takeaway about daily steps and mortality risk?\",\"answer\":\"Taking more steps per day is associated with progressively lower risk of all-cause mortality, with a plateau observed for adults aged 60 and older at about 6,000–8,000 steps per day.\"},{\"question\":\"How do SGLT2 inhibitors compare with DPP-4 inhibitors for recurrent gout flares?\",\"answer\":\"SGLT2 inhibitor initiation leads to a 34% lower rate of recurrent gout flares in patients with gout and type 2 diabetes compared with DPP-4 inhibitors, with similar findings across demographic subgroups.\"},{\"question\":\"What limitations are noted for the steps-and-mortality evidence?\",\"answer\":\"The conclusions are based on observational studies with higher risk of bias and confounding; steps were measured at a single time point, and participants were largely from high-income countries, limiting generalizability.\"}]","GEMs of the Week - Volume 3 - Issue 50 | PDF",1791057798,15]